c-Myc as a therapeutics target in cancer

Expert Review of Anticancer Therapy

Volumn 4, Issue 2, 2004, Pages 289-302

  Prochownik, Edward V ^a  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

Author keywords

Antisense oligonucleotides; c Myc; Chemotherapy; Mad; Max; Mga; Mnr; Mxil; Transcription

Indexed keywords

5 METHYLCYTOSINE; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; CAMPTOTHECIN; CISPLATIN; CYTOTOXIC AGENT; DOXORUBICIN; DRUG METABOLITE; ETOPOSIDE; GENE PRODUCT; IMATINIB; IRINOTECAN; LOCKED NUCLEIC ACID; MONOCLONAL ANTIBODY; MYC PROTEIN; OLIGONUCLEOTIDE; ONCOPROTEIN; PACLITAXEL; PEPTIDE NUCLEIC ACID; PHOSPHORODIAMIDATE MORPHOLINO OLIGONUCLEOTIDE; PORPHYRIN DERIVATIVE; PRODRUG; PROTAMINE KINASE; PROTEIN BCL 2; PROTEIN INHIBITOR; REGULATOR PROTEIN; RIBOZYME; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; ANTISENSE OLIGODEOXYNUCLEOTIDE;

BONE MARROW TOXICITY; CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CLINICAL TRIAL; DNA BINDING; DRUG POTENTIATION; DRUG TARGETING; GASTROINTESTINAL TOXICITY; GENE INTERACTION; GENE TARGETING; GENETIC CODE; GENETIC REGULATION; GENETIC TRANSCRIPTION; GENETIC TRANSFORMATION; HUMAN; MOLECULAR DYNAMICS; NONHUMAN; PROTEIN FAMILY; PROTEIN PROTEIN INTERACTION; REVIEW; RNA INTERFERENCE; RNA TRANSLATION; STRUCTURE ACTIVITY RELATION; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; TREATMENT OUTCOME; VIRAL GENE DELIVERY SYSTEM; ANIMAL; DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; GENETICS; METABOLISM; METHODOLOGY; NEOPLASM;

ANIMALS; DRUG DELIVERY SYSTEMS; HUMANS; NEOPLASMS; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; PROTO-ONCOGENE PROTEINS C-MYC;

EID: 1842790378     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.4.2.289     Document Type: Review

References (155)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 100(1), 57-67 (2000).
2. Hahn WC, Weinberg RA. Modeling the molecular circuitry of cancer. Nature Rev. Cancer 2(5), 331-341 (2002).
3. Cahill DP, Kinzler KW, Vogelstein B, Lengauer C. Genetic instability and Darwinian selection in tumors. Trends Cell Biol. 9(12), M57-M60 (1999).
4. Rajagopalan H, Nowak MA, Vogelstein B, Lengauer C. The significance of unstable chromosomes in colorectal cancer. Nature Rev. Cancer 3(9), 695-701 (2003).
5. Dredge K, Dalgleish AG, Marriott JB. Angiogenesis inhibitors in cancer therapy. Curr. Opin. Investig. Drugs 4(6), 667-674 (2003).
6. Sullivan DC, Bicknell R. New molecular pathways in angiogenesis. Br. J. Cancer 89(2), 228-231 (2003).
7. Rosenwald A, Staudt LM. Clinical translation of gene expression profiling in lymphomas and leukemias. Semin. Oncol. 29(3), 258-263 (2002).
8. van de Vijver MJ, He YD, van't Veer LJ et al. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347(25), 1999-2009 (2002).
9. O'Brien SG, Guilhot F, Larson RA et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med. 348(11), 994-1004 (2003).
10. Nesbit CE, Tersak JM, Prochownik EV. MYC oncogenes and human neoplastic disease. Oncogene 18(19), 3004-3016 (1999).
11. Boxer LM, Dang CV. Translocations involving c-myc and c-myc function. Oncogene 20(40), 5595-5610 (2001).
12. Hermeking H. The MYC oncogene as a cancer drug target. Curr. Cancer Drug Targets 3(3), 163-175 (2003).
13. Kim R, Tanabe K, Emi M, Uchida Y, Inoue H, Toge T. Inducing cancer cell death by targeting transcription factors. Anticancer Drugs 14(1), 3-11 (2003).
14. Lu X, Pearson A, Lunec J. The MYCN oncoprotein as a drug development target. Cancer Lett. 197(1-2), 125-130 (2003).
15. Pelengaris S, Khan M. The c-MYC oncoprotein as a treatment target in cancer and other disorders of cell growth. Expert Opin. Ther. Targets 7(5), 623-642 (2003).
16. Henriksson M, Luscher B. Proteins of the Myc network: essential regulators of cell growth and differentiation. Adv. Cancer Res. 68, 109-182 (1996).
17. Iritani BM, Eisenman RN. c-Myc enhances protein synthesis and cell size during B-lymphocyte development. Proc. Natl Acad. Sci. USA 96(23), 13180-13185 (1999).
18. Johnston LA, Prober DA, Edgar BA, Eisenman RN, Gallant P. Drosophila myc regulates cellular growth during development. Cell 98(6), 779-790 (1999).
19. Obaya AJ, Mateyak MK, Sedivy JM. Mysterious liaisons: The relationship between c-Myc and the cell cycle. Oncogene 18(19), 2934-2941 (1999).
20. Prendergast GC. Mechanisms of apoptosis by c-Myc. Oncogene 18(19), 2967-2987 (1999).
21. Yin XY, Grove L, Datta NS, Long MW, Prochownik EV. C-myc overexpression and p53 loss co-operate to promote genomic instability. Oncogene 18(5), 1177-1184 (1999).
22. Baudino TA, McKay C, Pendeville-Samain H et al. c-Myc is essential for vasculogenesis and angiogenesis during development and tumor progression. Genes Dev. 16(19), 2530-2543 (2002).
23. Fest T, Mougey V, Dalstein V et al. c-MYC overexpression in Ba/F3 cells simultaneously elicits genomic instability and apoptosis. Oncogene 21(19), 2981-2990 (2002).
24. Karlsson A, Deb-Basu D, Cherry A, Turner S, Ford J, Felsher DW. Defective double-strand DNA break repair and chromosomal translocations by MYC overexpression. Proc. Natl Acad. Sci. USA 100(17), 9974-9979 (2003).
25. Vafa O, Wade M, Kern S et al. c-Myc can induce DNA damage, increase reactive oxygen species and mitigate p53 function: A mechanism for oncogene-induced genetic instability. Mol. Cell 9(5), 1031-1044 (2002).
26. Davis AC, Wims M, Spotts GD, Hann SR, Bradley A. A null c-myc mutation causes lethality before 10.5 days of gestation in homozygotes and reduced fertility in heterozygous female mice. Genes Dev. 7(4), 671-682 (1993).
27. Askew DS, Ashmun RA, Simmons BC, Cleveland JL. Constitutive c-myc expression in an IL-3-dependent myeloid cell line suppresses cell cycle arrest and accelerates apoptosis. Oncogene 6(10),1915-1922 (1991).
28. Evan GI, Wyllie AH, Gilbert CS et al. Induction of apoptosis in fibroblasts by c-myc protein. Cell 69(1),119-128 (1992).
29. Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. Nature 411(6835), 342-348 (2001).
30. Cory S, Vaux DL, Strasser A, Harris AW, Adams JM. Insights from Bcl-2 and Myc: Malignancy involves abrogation of apoptosis as well as sustained proliferation. Cancer Res. 59(7 Suppl.), 1685S-1692S (1999).
31. Sherr CJ. The INK4a/ARF network in tumor suppression. Nature Rev. Mol. Cell. Biol. 2(10), 731-737 (2001).
32. Pelengaris S, Khan M, Evan GI. Suppression of Myc-induced apoptosis in β cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression. Cell 109(3), 321-334 (2002).
33. Dang CV. c-Myc target genes involved in cell growth, apoptosis and metabolism. Mol. Cell. Biol. 19(1), 1-11 (1999).
34. McArthur GA, Laherty CD, Queva C et al. The Mad protein family links transcriptional repression to cell differentiation. Cold Spring Harb. Symp. Quant. Biol. 63, 423-233 (1998).
35. Grandori C, Cowley SM, James LP, Eisenman RN. The Myc/Max/Mad network and the transcriptional control of cell behavior. Ann. Rev. Cell. Dev. Biol. 16, 653-699 (2000).
36. Baudino TA, Cleveland JL. The Max network gone mad. Mol. Cell. Biol. 21(3), 691-702 (2001).
37. Luscher B. Function and regulation of the transcription factors of the Myc/Max/Mad network. Gene 277(1-2), 1-14 (2001).
38. Luscher B, Larsson LG. The basic region/helix-loop-helix/leucine zipper domain of Myc proto-oncoproteins: function and regulation. Oncogene 18(19), 2955-2966 (1999).
39. Dang CV, McGuire M, Buckmire M, Lee WM. Involvement of the leucine zipper region in the oligomerization and transforming activity of human c-myc protein. Nature 337(6208), 664-666 (1989).
40. Smith MJ, Charron-Prochownik DC, Prochownik EV. The leucine zipper of c-Myc is required for fall inhibition of erythroleukemia differentiation. Mol. Cell. Biol. 10(10), 5333-5339 (1990).
41. Blackwood EM, Eisenman RN. Max: A helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc. Science 251(4998), 1211-1217 (1991).
42. Amati B, Dalton S, Brooks MW, Littlewood TD, Evan GI, Land H. Transcriptional activation by the human c-MYC oncoprotein in yeast requires interaction with Max. Nature 359(6394), 423-426 (1992).
43. Kretzner L, Blackwood EM, Eisenman RN. Transcriptional activities of the Myc and Max proteins in mammalian cells. Curr. Top. Microbiol. Immunol. 182, 435-443 (1992).
44. Kretzner L, Blackwood EM, Eisenman RN. Myc and Max proteins possess distinct transcriptional activities. Nature 359(6394), 426-429 (1992).
45. Amati B, Brooks MW, Levy N, Littlewood TD, Evan GI, Land H. Oncogenic activity of the c-Myc protein requires dimerization with Max. Cell 72(2), 233-245 (1993).
46. Amati B, Littlewood TD, Evan GI, Land H. c-Myc protein induces cell cycle progression and apoptosis through dimerization with Max. EMBO J. 12(13), 5083-5087 (1993).
47. Blackwell TK, Kretzner L, Blackwood EM, Eisenman RN, Weintraub H. Sequence-specific DNA binding by the c-Myc protein. Science 250(4984), 1149-1151 (1990).
48. Haggerty TJ, Zeller KI, Osthus RC, Wonsey DR, Dang CV. A strategy for identifying transcription factor binding sites reveals two classes of genomic c-Myc target sites. Proc. Natl Acad. Sci. USA 100(9), 5313-5318 (2003).
49. Oster SK, Ho CS, Soucie EL, Penn LZ. The myc oncogene: MarvelouslY Complex. Adv. Cancer Res. 84, 81-154 (2002).
50. Kato GJ, Barrett J, Villa-Garcia M, Dang CV. An amino-terminal c-myc domain required for neoplastic transformation activates transcription. Mol. Cell. Biol. 10(11), 5914-5920 (1990).
51. Nikiforov MA, Chandriani S, Park J et al. TRRAP-dependent and TRRAP-independent transcriptional activation by Myc family oncoproteins. Mol. Cell. Biol. 22(14), 5054-5063 (2002).
52. McMahon SB, Wood MA, Cole MD. The essential co-factor TRRAP recruits the histone acetyltransferase hGCN5 to c-Myc. Mol. Cell. Biol. 20(2), 556-562 (2000).
53. Park J, Kunjibettu S, McMahon SB, Cole MD. The ATM-related domain of TRRAP is required for histone acetyltransferase recruitment and Myc-dependent oncogenesis. Genes Dev. 15(13), 1619-1624 (2001).
54. Frank SR, Schroeder M, Fernandez P, Taubert S, Amati B. Binding of c-Myc to chromatin mediates mitogen-induced acetylation of histone H4 and gene activation. Genes Dev. 15(16), 2069-2082 (2001).
55. Frank SR, Parisi T, Taubert S et al. MYC recruits the TIP60 histone acetyltransferase complex to chromatin. EMBO Rep. 4(6), 575-580 (2003).
56. MacGregor D, Li LH, Ziff EB. Dominant negative mutants of Myc inhibit co-operation of both Myc and adenovirus serotype-5 E1a with Ras. J. Cell. Physiol. 167(1), 95-105 (1996).
57. Wood MA, McMahon SB, Cole MD. An ATPase/helicase complex is an essential co-factor for oncogenic transformation by c-Myc. Mol. Cell 5(2), 321-330 (2000).
58. Park J, Wood MA, Cole MD. BAF53 forms distinct nuclear complexes and functions as a critical c-Myc-interacting nuclear co-factor for oncogenic transformation. Mol. Cell. Biol. 22(5), 1307-1316 (2002).
59. Hurlin PJ, Zhou ZQ, Toyo-Oka K et al. Deletion of Mnt leads to disrupted cell cycle control and tumorigenesis. EMBO J. 22, 4584-4596 (2003).
60. Hurlin PJ, Steingrimsson E, Copeland NG et al. Mga, a dual-specificity transcription factor that interacts with Max and contains a T-domain DNA-binding motif. EMBO J. 18, 7019-7028 (1999).
61. Larsson LG, Bahram F, Burkhardt H, Luscher B. Analysis of the DNA-binding activities of Myc/Max/Mad network complexes during induced differentiation of U-937 monoblasts and F9 teratocarcinoma cells. Oncogene 15(6), 737-748 (1997).
62. Queva C, Hurlin PJ, Foley KP, Eisenman RN. Sequential expression of the MAD family of transcriptional repressors during differentiation and development. Oncogene 16(8), 967-977 (1998).
63. O'Hagan RC, Schreiber-Agus N, Chen K et al. Gene-target recognition among members of the myc superfamily and implications for oncogenesis. Nature Genet. 24(2), 113-119 (2000).
64. James L, Eisenman RN. Myc and Mad bHLHZ domains possess identical DNA-binding specificities but only partially overlapping functions in vivo. Proc. Natl Acad. Sci. USA 99(16), 10429-10434 (2002).
65. Ayer DE, Lawrence QA, Eisenman RN. Mad-Max transcriptional repression is mediated by ternary complex formation with mammalian homologs of yeast repressor Sin3. Cell 80(5), 767-776 (1995).
66. Schreiber-Agus N, Chin L, Chen K et al. An amino-terminal domain of Mxi1 mediates antiMyc oncogenic activity and interacts with a homolog of the yeast transcriptional repressor SIN3. Cell 80(5), 777-786 (1995).
67. Brubaker K, Cowley SM, Huang K et al. Structure of the interacting domains of the Mad-Sin3 complex: Implications for recruitment of a chromatin-modifying complex. Cell 103(4), 655-665 (2000).
68. Alland L, Muhle R, Hou H Jr et al. Role for N-CoR and histone deacetylase in Sin3-mediated transcriptional repression. Nature 387(6628), 49-55 (1997).
69. Laherty CD, Yang WM, Sun JM, Davie JR, Seto E, Eisenman RN. Histone deacetylases associated with the mSin3 corepressor mediate mad transcriptional repression. Cell 89(3), 349-356 (1997).
70. Sklar MD, Prochownik EV. Modulation of cisplatinum resistance in Friend erythroleukemia cells by c-myc. Cancer Res. 51(8), 2118-2123 (1991).
71. Mizutani Y, Fukumoto M, Bonavida B, Yoshida O. Enhancement of sensitivity of urinary bladder tumor cells to cisplatin by c-myc antisense oligonucleotide. Cancer 74(9), 2546-2554 (1994).
72. Van Waardenburg RC, Prins J, Meijer C, Uges DR, De Vries EG, Mulder NH. Effects of c-myc oncogene modulation on drug resistance in human small cell lung carcinoma cell lines. Anticancer Res. 16(4A),1963-1970 (1996).
73. Citro G, D'Agnano I, Leonetti C et al. c-myc antisense oligodeoxynucleotides enhance the efficacy of cisplatin in melanoma chemotherapy in vitro and in nude mice. Cancer Res. 58(2), 283-289 (1998).
74. Nesbit CE, Grove LE, Yin X, Prochownik EV. Differential apoptotic behaviors of c-myc, N-myc and L-myc oncoproteins. Cell Growth Differ. 9(9), 731-741 (1998).
75. Felsher DW, Bishop JM. Transient excess of MYC activity can elicit genomic instability and tumorigenesis. Proc. Natl Acad. Sci. US4 96(7), 3940-3944 (1999).
76. Jain M, Arvanitis C, Chu K et al. Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science 297(5578), 102-104 (2002).
77. Mu ZM, Yin XY, Prochownik EV. Pag, a putative tumor suppressor, interacts with the Myc Box II domain of c-Myc and selectively alters its biological function and target gene expression. J. Biol. Chem. 277(45), 43175-43184 (2002).
78. Neumann CA, Krause DS, Carman CV et al. Essential role for the peroxiredoxin Prdx1 in erythrocyte anti-oxidant defense and tumor suppression. Nature 424(6948), 561-565 (2003).
79. Soucek L, Evan G. Myc: Is this the oncogene from Hell? Cancer Cell 1(5), 406-408 (2002).
80. Giovannangeli C, Helene C. Triplex-forming molecules for modulation of DNA information processing. Curr. Opin. Mol. Ther. 2(3), 288-296 (2000).
81. Rapozzi V, Cogoi S, Spessotto P et al. Antigene effect in K562 cells of a PEG-conjugated triplex-forming oligonucleotide targeted to the bcr/abl oncogene. Biochemistry 41(2), 502-510 (2002).
82. Behe MJ. An overabundance of long oligopurine tracts occurs in the genome of simple and complex eukaryotes. Nucleic Acids Res. 23(4), 689-695 (1995).
83. Brown PM, Fox KR. Nucleosome core particles inhibit DNA triple helix formation. Biochem. J. 319(Pt 2), 607-611 (1996).
84. Casey BP, Glazer PM. Gene targeting via triple-helix formation. Prog. Nucleic Acid Res. Mol. Biol. 67, 163-192 (2001).
85. Siddiqui-Jain A, Grand CL, Bearss DJ, Hurley LH. Direct evidence for a G-quadruplex in a promoter region and its targeting with a small molecule to repress c-MYC transcription. Proc. Natl Acad. Sci. USA 99(18), 11593-11598 (2002).
86. Korinek V, Barker N, Morin PJ et al. Constitutive transcriptional activation by a β-catenin-Tcf complex in APC-/- colon carcinoma. Science 275(5307), 1784-1787 (1997).
87. Morin PJ, Sparks AB, Korinek V et al. Activation of β-catenin-Tcf signaling in colon cancer by mutations in β -catenin or APC. Science 275(5307), 1787-1790 (1997).
88. Miyoshi H, Kozu T, Shimizu K et al. The t(8;21) translocation in acute myeloid leukemia results in production of an AML1-MTG8 fusion transcript. EMBO J. 12(7), 2715-2721 (1993).
89. Pabst T, Mueller BU, Harakawa N et al. AML1-ETO downregulates the granulocytic differentiation factor C/EBPα in t(8;21) myeloid leukemia. Nature Med. 7(4), 444-451 (2001).
90. Johansen LM, Iwama A, Lodie TA et al. c-Myc is a critical target for c/EBPα in granulopoiesis. Mol. Cell. Biol. 21(11), 3789-3806 (2001).
91. Gewirtz AM, Sokol DL, Ratajczak MZ. Nucleic acid therapeutics: State of the art and future prospects. Blood 92(3), 712-736 (1998).
92. Wang JL, Liu D, Zhang ZJ et al. Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc. Natl Acad. Sci. USA 97(13), 7124-7129 (2000).
93. Opalinska JB, Gewirtz AM. Nucleic-acid therapeutics: Basic principles and recent applications. Nature Rev. Drug Discov. 1(7), 503-514 (2002).
94. Tortora G, Ciardiello F. Antisense strategies targeting protein kinase C: Preclinical and clinical development. Semin. Oncol. 30(4 Suppl. 10), 26-31 (2003).
95. Stahel RA, Zangemeister-Wittke U. Antisense oligonucleotides for cancer therapy: An overview. Lung Cancer 41(Suppl. 1), S81-S88 (2003).
96. Holt JT, Redner RL, Nienhuis AW. An oligomer complementary to c-myc mRNA inhibits proliferation of HL-60 promyelocytic cells and induces differentiation. Mol. Cell. Biol. 8(2), 963-973 (1988).
97. Loke SL, Stein C, Zhang X, Avigan M, Cohen J, Neckers LM. Delivery of c-myc antisense phosphorothioate oligodeoxynucleotides to hematopoietic cells in culture by liposome fusion: Specific reduction in c-myc protein expression correlates with inhibition of cell growth and DNA synthesis. Curr. Top. Microbiol. Immunol. 141, 282-289 (1988).
98. Prochownik EV, Kukowska J, Rodgers C. c-myc antisense transcripts accelerate differentiation and inhibit G1 progression in murine erythroleukemia cells. Mol. Cell. Biol. 8(9), 3683-3695 (1988).
99. Leonetti C, D'Agnano I, Lozupone F et al. Antitumor effect of c-myc antisense phosphorothioate oligodeoxynucleotides on human melanoma cells in vitro and in mice. J. Natl Cancer Inst. 88(7), 419-429 (1996).
100. Pastorino F, Brignole C, Marimpietri D et al. Targeted liposomal c-myc antisense oligodeoxynucleotides induce apoptosis and inhibit tumor growth and metastases in human melanoma models. Clin. Cancer Res. 9(12), 4595-4605 (2003).
101. Iversen PL, Arora V, Acker AJ, Mason DH, Devi GR. Efficacy of antisense morpholino oligomer targeted to c-myc in prostate cancer xenograft murine model and a Phase I safety study in humans. Clin. Cancer Res. 9(7), 2510-2519 (2003).
102. Knapp DC, Mata JE, Reddy MT, Devi GR, Iversen PL. Resistance to chemotherapeutic drugs overcome by c-Myc inhibition in a Lewis lung carcinoma murine model. Anticancer Drugs 14(1), 39-47 (2003).
103. Arora V, Knapp DC, Smith BL et al. c-Myc antisense limits rat liver regeneration and indicates role for c-Myc in regulating cytochrome P450 3A activity. J. Pharmacol. Exp. Ther. 292(3), 921-928 (2000).
104. Devi GR, Oldenkamp JR, London CA, Iversen PL. Inhibition of human chorionic gonadotropin β-subunit modulates the mitogenic effect of c-myc in human prostate cancer cells. Prostate 53(3), 200-2010 (2002).
105. Menchise V, De Simone G, Tedeschi T et al. Insights into peptide nucleic acid (PNA) structural features: The crystal structure of a D-lysine-based chiral PNA-DNA duplex. Proc. Natl Acad. Sci. USA 100(21), 12021-12026 (2003).
106. Pooga M, Langel U. Targeting of cancer-related proteins with PNA oligomers. Curr. Cancer Drug Targets 1(3), 231-239 (2001).
107. Pooga M, Soomets U, Bartfai T, Langel U. Synthesis of cell-penetrating peptide-PNA constructs. Methods Mol. Biol. 208, 225-236 (2002).
108. Elayadi AN, Corey DR. Application of PNA and LNA oligomers to chemotherapy. Curr. Opin. Investig. Drugs 2(4), 558-561 (2001).
109. Orum H, Wengel J. Locked nucleic acids: A promising molecular family for gene-function analysis and antisense drug development. Curr. Opin. Mol. Ther. 3(3), 239-243 (2001).
110. Paddison PJ, Hannon GJ. RNA interference: The new somatic cell genetics? Cancer Cell 2(1), 17-23 (2002).
111. Tijsterman M, Ketting RF, Plasterk RH. The genetics of RNA silencing. Ann. Rev. Genet. 36, 489-519 (2002).
112. Lu PY, Xie FY, Woodle MC. siRNA-mediated antitumorigenesis for drug target validation and therapeutics. Curr. Opin. Mol. Ther. 5(3), 225-234 (2003).
113. Cheng J, Luo J, Zhang X et al. Inhibition of cell proliferation in HCC-9204 hepatoma cells by a c-myc specific ribozyme. Cancer Gene Ther. 7(3), 407-412 (2000).
114. Qin XF, An DS, Chen IS, Baltimore D. Inhibiting HIV-1 infection in human T-cells by lentiviral-mediated delivery of small interfering RNA against CCR5. Proc. Natl Acad. Sci. USA 100(1), 183-188 (2003).
115. Turner R, Tjian R. Leucine repeats and an adjacent DNA binding domain mediate the formation of functional cFos-cJun heterodimers. Science 243(4899), 1689-1694 (1989).
116. Foster BA, Coffey HA, Morin MJ, Rastinejad F. Pharmacological rescue of mutant p53 conformation and function. Science 286(5449), 2507-2510 (1999).
117. Komarov PG, Komarova EA, Kondratov RV et al. A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science 285(5434), 1733-1737 (1999).
118. Berg T, Cohen SB, Desharnais J et al. Small-molecule antagonists of Myc/Max dimerization inhibit Myc-induced transformation of chicken embryo fibroblasts. Proc. Natl Acad. Sci. USA 99(6), 3830-3835 (2002).
119. Bowman T, Broome MA, Sinibaldi D et al. Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis. Proc. Natl Acad. Sci. USA 98(13), 7319-7324 (2001).
120. Yin X, Giap C, Lazo JS, Prochownik EV. Low-molecular-weight inhibitors of Myc-Max interaction and function. Oncogene 22(40), 6151-6159 (2003).
121. Chen J, Willingham T, Margraf LR, Schreiber-Agus N, DePinho RA, Nisen PD. Effects of the MYC oncogene antagonist, MAD, on proliferation, cell cycling and the malignant phenotype of human brain tumor cells. Nature Med 1(7), 638-643 (1995).
122. Hurlin PJ, Queva C, Koskinen PJ et al. Mad3 and Mad4: Novel Max-interacting transcriptional repressors that suppress c-myc dependent transformation and are expressed during neural and epidermal differentiation. EMBO J. 14(22), 5646-5659 (1995).
123. Roussel MF, Ashmun RA, Sherr CJ, Eisenman RN, Ayer DE. Inhibition of cell proliferation by the Mad1 transcriptional repressor. Mol. Cell. Biol. 16(6), 2796-2801 (1996).
124. Wu S, Pena A, Korcz A, Soprano DR, Soprano KJ. Overexpression of Mxi1 inhibits the induction of the human ornithine decarboxylase gene by the Myc/Max protein complex. Oncogene 12, 621-629 (1996).
125. Wechsler DS, Shelly CA, Petroff CA, Dang CV. MXI1, a putative tumor suppressor gene, suppresses growth of human glioblastoma cells. Cancer Res. 57(21), 4905-4912 (1997).
126. Gagandeep S, Ott M, Nisen PD, DePinho RA, Gupta S. Overexpression of Mad transcription factor inhibits proliferation of cultured human hepatocellular carcinoma cells along with tumor formation in immunodeficient animals. J. Gene Med. 2(2), 117-1127 (2000).
127. Gunes C, Lichtsteiner S, Vasserot AP, Englert C. Expression of the hTERT gene is regulated at the level of transcriptional initiation and repressed by Mad1. Cancer Res. 60(8), 2116-2121 (2000).
128. Cerni C, Skrzypek B, Popov N et al. Repression of in vivo growth of Myc/Ras transformed tumor cells by Mad1. Oncogene 21(3), 447-459 (2002).
129. Manni I, Tunici P, Cirenei N et al. Mxi1 inhibits the proliferation of U87 glioma cells through downregulation of cyclin B1 gene expression. Br. J. Cancer 86(3), 477-484 (2002).
130. Sawyers CL, Callahan W, Witte ON. Dominant negative MYC blocks transformation by ABL oncogenes. Cell 70(6), 901-910 (1992).
131. Spotts GD, Patel SV, Xiao Q, Hann SR. Identification of downstream-initiated c-Myc proteins which are dominant-negative inhibitors of transactivation by full-length c-Myc proteins. Mol. Cell. Biol. 17(3), 1459-1468 (1997).
132. Nesbit CE, Tersak JM, Grove LE, Drzal A, Choi H, Prochownik EV. Genetic dissection of c-myc apoptotic pathways. Oncogene 19(28), 3200-3212 (2000).
133. Draeger LJ, Mullen GP. Interaction of the bHLH-zip domain of c-Myc with H1-type peptides. Characterization of helicity in the H1 peptides by NMR. J. Biol. Chem. 269(3), 1785-1793 (1994).
134. Giorello L, Clerico L, Pescarolo MP et al. Inhibition of cancer cell growth and c-Myc transcriptional activity by a c-Myc helix 1-type peptide fused to an internalization sequence. Cancer Res. 58(16), 3654-3659 (1998).
135. Wadia JS, Dowdy SF. Modulation of cellular function by TAT mediated transduction of full length proteins. Curr. Protein Pept. Sci. 4(2), 97-104 (2003).
136. Gait MJ. Peptide-mediated cellular delivery of antisense oligonucleotides and their analogues. Cell. Mol. Life Sci. 60(5), 844-853 (2003).
137. Lehrmann H, Pritchard LL, Harel-Bellan A. Histone acetyltransferases and deacetylases in the control of cell proliferation and differentiation. Adv. Cancer Res. 86, 41-65 (2002).
138. Kim DH, Kim M, Kwon HJ. Histone deacetylase in carcinogenesis and its inhibitors as anticancer agents. J. Biochem. Mol. Biol. 36(1), 110-119 (2003).
139. Bielinska A, Shivdasani RA, Zhang LQ, Nabel GJ. Regulation of gene expression with double-stranded phosphorothioate oligonucleotides. Science 250(4983), 997-1000 (1990).
140. Ahn JD, Kim CH, Magae J et al. E2F decoy oligodeoxynucleotides effectively inhibit growth of human tumor cells. Biochem. Biophys. Res. Commun. 310(4), 1048-1053 (2003).
141. Morishita R, Gibbons GH, Horiuchi M et al. A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo. Proc. Natl Acad. Sci. USA 92(13), 5855-5859 (1995).
142. Novak EM, Metzger M, Chammas R et al. Downregulation of TNF-α and VEGF expression by Sp1 decoy oligodeoxynucleotides in mouse melanoma tumor. Gene Ther. 10(23), 1992-1997 (2003).
143. Mann MJ, Whittemore AD, Donaldson MC et al. Ex vivo gene therapy of human vascular bypass grafts with E2F decoy: The PREVENT single-centre, randomised, controlled trial. Lancet 354(9189), 1493-1498 (1999).
144. Moberg KH, Tyndall WA, Pyrc J, Hall DJ. Analysis of the c-myc P2 promoter. J. Cell. Physiol. 148(1), 75-84 (1991).
145. Megosh L, Gilmour SK, Rosson D et al. Increased frequency of spontaneous skin tumors in transgenic mice which overexpress ornithine decarboxylase. Cancer Res. 55(19), 4205-4209 (1995).
146. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nature Med. 9(6), 669-676 (2003).
147. Kabbinavar F, Hurwitz HI, Fehrenbacher L et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J. Clin. Oncol. 21(1), 60-65 (2003).
148. Yang JC, Haworth L, Sherry RM et al. A randomized trial of bevacizumab, an antivascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med. 349(5), 427-434 (2003).
149. Incles CM, Schultes CM, Neidle S. Telomerase inhibitors in cancer therapy: Current status and future directions. Curr. Opin. Investig. Drugs 4(6), 675-685 (2003).
150. Huang J, Frischer JS, Serur A et al. Regression of established tumors and metastases by potent vascular endothelial growth factor blockade. Proc. Natl Acad. Sci. USA 100(13), 7785-7790 (2003).
151. Kumagai T, Tanio Y, Osaki T et al. Eradication of Myc-overexpressing small cell lung cancer cells transfected with herpes simplex virus thymidine kinase gene containing Myc-Max response elements. Cancer Res. 56(2), 354-358 (1996).
152. Pawlik CA, Iyengar RV, Krull EJ et al. Use of the ornithine decarboxylase promoter to achieve N-MYC-mediated overexpression of a rabbit carboxylesterase to sensitize neuroblastoma cells to CPT-11. Mol. Ther. 1(5 Pt 1), 457-463 (2000).
153. Stubdal H, Perin N, Lemmon M et al. A prodrug strategy using ONYX-015-based replicating adenoviruses to deliver rabbit carboxylesterase to tumor cells for conversion of CPT-11 to SN-38. Cancer Res. 63(20), 6900-6908 (2003).
154. Berberich SJ, Cole MD. Casein kinase II inhibits the DNA-binding activity of Max homodimers but not Myc/Max heterodimers. Genes Dev. 6(2), 166-176 (1992).
155. Prochownik EV, VanAntwerp ME. Differential patterns of DNA binding by myc and Max proteins. Proc. Natl Acad. Sci. USA 90(3), 960-964 (1993).